Paradigm Genetics (PDGM) - 500 Beiträge pro Seite

[genetic]

Schaut Euch doch mal den morgen erscheinenden Quartalsbericht an, da dürfte der Kurs wieder in alte Höhen steigen.
http://biz.yahoo.com/prnews/010502/chw023.html

[genetic]

Sieht ja prächtig aus !!!

[thebull 2]

nicht schlecht.
hier mal der ganze bericht von deiner adresse
Wednesday May 2, 4:30 pm Eastern Time

Press Release

SOURCE: Paradigm Genetics, Inc.

Paradigm Genetics Announces First Quarter Financial Results, Revenues
Increase 819%

Company Exceeds Analysts` Quarterly Consensus Earnings Estimate As Reported by First Call by
Two Cents

RESEARCH TRIANGLE PARK, N.C., May 2 /PRNewswire/ --

Paradigm Genetics, Inc. (Nasdaq: PDGM - news), a functional genomics company, today reported financial results for the first
quarter ended March 31, 2001.

For the three months ended March 31, 2001 total revenues increased 819% to $5.5 million, compared to approximately
$593,000 for the same period in 2000. The increase in revenue was due to higher throughput from Paradigm`s Gene Function
Factory(TM) relating to the company`s commercial partnerships with Bayer AG and Monsanto Company.

Total operating expenses for the three months ended March 31, 2001, excluding non-cash compensation charges, increased 84%
to $9.3 million compared, to $5.0 million for the same period in 2000. The majority of the increase in operating expenses resulted
from variable costs associated with higher throughput in the GeneFunction Factory(TM), an acceleration of Paradigm`s metabolic
profiling research, and the company`s continued investment in informatics-based technologies. Between March 31, 2000 and
March 31, 2001 the company added 78 research scientists and 12 employees in business development and operations.

Including non-cash compensation charges, the company reported a first- quarter 2001 net loss attributable to common
stockholders of $4.0 million, or $0.15 per common share, which was 2 cents better than the consensus earnings estimate reported
by First Call. This compares to a net loss of $16.8 million, or $3.11 per common share for the same period in 2000. Excluding the
non-cash compensation charges, the net loss for the three months ended March 31, 2001 would have been $3.7 million, or $0.14
per common share.

``We are off to a good start in 2001 and continue to meet the goals we have laid out for ourselves`` said John A. Ryals, Ph.D.,
Chief Executive Officer of Paradigm Genetics. ``We have started commercial production in our new third- generation,
state-of-the-art GeneFunction Factory(TM). Our first quarter revenues and expenses were 21% and 6% higher, respectively, than
during the last quarter of 2000, demonstrating the impact of higher throughput in our GeneFunction Factory(TM). Also, we are
continuing to invest in technologies such as metabolomics and informatics that we believe will leverage the gene function data
produced by our factory and help secure our long-term competitive position.``

Highlights

* Paradigm met its scheduled milestone and delivered another herbicide
assay to Bayer during the first-quarter of 2001.
* Paradigm exceeded the scheduled milestone deliverables in its commercial
partnership with Monsanto by 20%, resulting in an accelerated milestone
payment.
* Paradigm published its Transposon-Arrayed Gene Knock-Out (TAG-KO(TM))
technology, a functional genomics method that can be used to discover
and mutate genes in organisms with large genomes in which the sequence
is not necessarily known. These results, from research conducted in
fungi, were published in the Proceedings of the National Academy of
Sciences.


About Paradigm Genetics

Paradigm Genetics is industrializing the process of gene function discovery for four major sectors of the global economy: human health, nutrition, crop production,
and industrial products. The company has designed the GeneFunction Factory(TM) - an integrated, rapid, industrial-scale laboratory through which it discovers gene
function. Paradigm and its strategic partners intend to develop novel products using information developed with the GeneFunction Factory(TM). Paradigm`s
GeneFunction factory(TM) is based on a state of the art phenomics platform integrated with metabolic profiling and gene expression profiling technologies. The
backbone of the GeneFunction Factory(TM) is the company`s proprietary FunctionFinder(TM) bioinformatics system, used to collect, store, analyze, and retrieve
information. For more information visit www.paradigmgenetics.com.

Note: Paradigm will host a conference call at 8:30 AM EST on Thursday, May 3, 2001 to review financial results for the three months ended March 31, 2001. This
call will be broadcast simultaneously via the Internet at www.paradigmgenetics.com and will be accessible through the investor relations section and homepage of
Paradigm`s web site through May 17, 2001. Contact Investor Relations at [phone] for information on accessing a taped replay via telephone.

PARADIGM GENETICS, INC.
CONDENSED STATEMENTS OF OPERATIONS

Three Months Ended
March 31,
(unaudited)
2001 2000

Revenues:
Commercial partnerships $5,385,805 $468,220
Grant revenues 64,863 125,001
Total revenues 5,450,668 593,221

Operating expenses:
Research and development (includes $188,252
and $102,352 of stock based compensation
expense for the three months ended March 31,
2001 and March 31, 2000, respectively) 6,395,358 3,102,719

Selling, general and administrative (includes
$148,472 and $247,630 of stock based
compensation expense for the three months
ended March 31, 2001 and March 31,
2000 respectively) 3,219,605 2,283,893

Total operating expenses 9,614,963 5,386,612

Loss from operations (4,164,295) (4,793,391)

Other income (expense):
Interest income 631,851 296,993
Interest expense (477,359) (279,875)
Other income (expense), net 154,492 17,118

Net loss (4,009,803) (4,776,273)

Beneficial conversion feature of
Series C Preferred Stock -- (12,000,000)

Net loss attributable to common
stockholders $(4,009,803) $(16,776,273)

Net loss per share attributable to
common stockholders - basic and diluted $ (0.15) $ (3.11)

Weighted average common shares
outstanding - basic and diluted 26,097,515 5,394,915


Paradigm Genetics, Inc.
2001 First-Quarter Results
Condensed Balance Sheet Data

March 31, December 31,
2001 2000
(unaudited)

Assets:
Cash, cash equivalents, short-term
investments $27,558,785 $35,999,676
Other current assets 5,010,109 5,101,648
Total Current Assets 32,568,894 41,101,324
Property plant & equipment net 25,371,652 23,763,502
Other noncurrent assets 10,758,266 10,599,920
Total Assets $68,698,812 $75,464,746
Liabilities and Stockholders`
Equity (Deficit):
Current liabilities 22,739,918 25,097,865
Long-term obligations 9,801,253 10,753,355
Stockholders` equity 36,157,641 39,613,526
Total Liabilities and Stockholders`
Equity (Deficit) $68,698,812 $75,464,746



This press release contains forward-looking statements, including statements regarding Paradigm`s ability to successfully develop its GeneFunction Factory(TM) and
other technologies; Paradigm`s ability to industrialize the process of gene function discovery for four major sectors of the global economy: human health, nutrition,
crop production, and industrial products; and Paradigm`s ability to secure its long-term competitive position. Such statements are based on management`s current
expectations and are subject to a number of risks, factors and uncertainties that may cause actual results, events and performance to differ materially from those
referred to in the forward-looking statements. These risks include, but are not limited to, Paradigm`s early stage of development, history of net losses, technological
and product development uncertainties, reliance on research collaborations, uncertainty of additional funding and ability to protect its patents and proprietary rights.
These and other risks are identified in Paradigm`s report on Form 10-K for the year ended December 31, 2000, filed with the Securities and Exchange Commission.

GeneFunction Factory(TM) and FunctionFinder(TM) are U.S. trademarks of Paradigm Genetics, Inc.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X79936878

SOURCE: Paradigm Genetics, Inc.

gruss
tb 2